Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (August 2023)
20 slides from Bio-gene Technology's investor presentation, Aug 11, 2023
Slide 1: Bio-Gene Technology Limited FY23 Business Update
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED 11 AUGUST 2023 FY23 Business Update PRESENTED BY Richard Jagger CEO Rod Valencia CFO & Co. Sec. FY23 Business Update
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation
Slide 3: Agenda
AGENDA • Bio-Gene Business Overview • Performance Highlights • Operational Update • FY23 Financials • Outlook • Q&A FY23 Business Update 3
Slide 4: Global Challenges and Resistant Pest Control
GLOBAL CHALLENGES AND RESISTANT PEST CONTROL Food Security & Public Health • Growing population = more food “Without Crop Protection, crop • Climate change = more mosquitos losses would double each year” CropLife Financial Impact • Production lost to pests = higher costs, lost income “No new public
Slide 5: Bio-Gene's Chemistry Is a Step-Change for Resistant Pest Control
BIO-GENE'S CHEMISTRY IS A STEP-CHANGE FOR RESISTANT PEST CONTROL • Novel Mode of Action (MoA) • Last new MoA commercialised in 2008, with current sales of US$2.3bn • Naturally derived and safe chemistry • Efficacy across a number of target pests QcideTM FlavocideTM • Addresses multiple market segmen
Slide 6: Bio-Gene's Products Target Key Market Segments
BIO-GENE’S PRODUCTS TARGET 5 KEY MARKET SEGMENTS 52% Crop Protection Food, Fibre & Includes Grain storage Grain Storage segment, valued at ~ US$1 billion US$31.1bn Addressable Market 13% 16% Consumer Applications Sprays, 19% Creams, Lotions Public Health & Personal Vector Control for Repellents Mala
Slide 7: FY23 Performance Highlights
FY23 PERFORMANCE HIGHLIGHTS Key developments achieved in FY23 collectively pave a clear path towards commercialisation FY23 Key Achievements US$31.1 billion STK Clarke Synergy Patent Addressable Market GRDC Support Agreement Extension Results Protection US$1Bn Stored Grain US$4Bn Public Health Consu
Slide 8: Operational Update
OPERATIONAL UPDATE FY23 Business Update
Slide 9: Strategy
STRATEGY Commercialisation pathway • Active ingredient registrations • Product development, marketing & distribution with strong commercial partners • Developing additional IP, proprietary manufacturing & production know-how Revenue drivers • Technology licensing fees • Milestone payments • Active i
Slide 10: Revenue Profile Expectations
REVENUE PROFILE EXPECTATIONS FY 2023 FY 2027 FY 2031 ✓ Active ingredients first registrations ✓ Expanding commercialised product driving ✓ Registration and Commercial ✓ Products developed can go to market significant increase in royalty payments development stage ✓ High margins ✓ Licence fees, miles
Slide 11: Commercial Partnership Snapshot
COMMERCIAL PARTERNSHIP SNAPSHOT “ Additional opportunities with other commercial partners advancing Our key and STK applies advanced botanical Clarke is the largest vertically Evergreen is a market leader in consumer products across Europe expanding science and bio-ag technology in integrated compan
Slide 12: Commercial FY23 Advancement Summary
COMMERCIAL FY23 ADVANCEMENT SUMMARY Commercial partnerships and third-party validation are critical for our business progression Partnership Advancement Made Value Add STK Completion of STK agreement for Qcide ✓ STK fully funds multi-million dollar Qcide registration cost ✓ BGT retains full commerci
Slide 13: Operational Advancements
OPERATIONAL ADVANCEMENTS Intellectual property advancements are critical to the value of BGT to our customers Synergy leads to new partner evaluation • Significant opportunity to reduce insecticide load, address resistance, reduce cost & support post-patent strategies for partners. • Opens broader m
Slide 14: Leadership Team Evolves for Next Stage of Growth
LEADERSHIP TEAM EVOLVES FOR NEXT STAGE OF GROWTH • Appointment of Alex Ding as Chair upon retirement of Robert Klupacs • Appointment of Tim Grogan as new CEO • Richard Jagger focusing on commercial partnerships • Follows on from: • Appointment of Chris Ramsay as new Non-Executive Director • Appointm
Slide 15: FY23 Financials
FY23 FINANCIALS FY23 Business Update
Slide 16: Financial Update – Key Metrics
FINANCIAL UPDATE – KEY METRICS AUD ($‘000) FY22 FY23 • FY23 Commentary Revenue 446 149 • Revenue includes milestone payments $150k Other income 493 532 • Other income includes R&D refund ~$440k Reported Net Loss (2,914) (3,096) per year FY22 FY23 • Net cash Used in Operations included: Net Cash Used
Slide 17: Commercialisation Pathway and Capital Intensity
COMMERCIALISATION PATHWAY AND CAPITAL INTENSITY Commercialisation Pathway Current Initiatives Capital Intensity • Active ingredient registrations • Investment to register active • Qcide registration – no (minimal) ingredient significant cost • STK deal (significant financial • Capital intensity – be
Slide 18: Outlook
OUTLOOK FY23 Business Update
Slide 19: Outlook
OUTLOOK • Additional synergy/efficacy testing • Advance other commercial partnerships • Deliver manufacturing partnerships • Advance our regulatory applications with governing bodies • Continue to advance our business model via licences, milestones, active ingredient sales & royalties FY23 Business
Slide 20: Q&A
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED Q&A FY23 Business Update
Bio-gene Technology — Investor Presentation (August 2023) on 6ix